sacubitril/valsartan for Heart Failure
This trial looks at the long-term safety and tolerability of a heart failure drug.
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2019 Phase 3 trial • 2572 Patients • NCT03066804
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Are middle-aged individuals being accepted into this research project?
"Children aged 1 year to 18 years old are eligible for this clinical trial. In total, there are 25 clinical trials for patients under 18 and 758 for people 65 and older."
Could I qualify to join this experiment?
"This study, which is looking for 217 individuals with a history of heart failure, has the following requirements for applicants: They must have given informed consent, be taking the study drug at the EOS visit for PANORAMA-HF Part 2, and not have any major safety concerns."
What is the primary medical condition that sacubitril/valsartan is indicated for?
"sacubitril/valsartan is most often given to patients with left ventricular dysfunction. It can also be used to lower blood pressure in patients that haven't respond well to other treatments and to prevent cardiovascular events."
Is this the first time that sacubitril/valsartan is being trialed?
"There are currently 39 different ongoing clinical trials for sacubitril/valsartan. Phase 3 trials, which are the most advanced, are being conducted at 8 of those locations. Most of the research is taking place in Montreal, Quebec, but there are 812 sites total."
What are some known risks associated with sacubitril/valsartan?
"Although it is still in Phase 3, sacubitril/valsartan has shown efficacy in some patients and has been proven to be safe multiple times. Therefore, it received a score of 3."